Vaccine Innovator VitriVax Raises $17.25 Million Series B to Advance Stable Formulations

Biotech startup VitriVax closed a $17.25 million Series B round to expand its heat-stable vaccine formulation platform aimed at global distribution without cold-chain requirements. The company plans to scale clinical manufacturing and advance trials for multiple immunizations, including malaria and influenza. CEO Dr. Drew McCall said the technology could cut distribution costs by up to 60%. Investors include health-impact funds and strategic pharma partners. Analysts expect VitriVax’s approach to transform last-mile vaccine delivery in developing markets and support pandemic-preparedness initiatives backed by global health agencies.